Referred to the House Committee on Energy and Commerce.
The bill authorizes the Secretary of Health and Human Services to conduct and support research and to develop evidence-based strategies to increase early detection of and intervention for uterine fibroids. It allows the Secretary to award grants to States to implement programs (including screening and advanced gynecological imaging, patient navigation, public awareness campaigns, and measures to facilitate access) and gives priority to programs serving socially vulnerable populations at elevated risk.
Funding and scope: liberals expect robust funding and coverage actions; conservatives worry about open-ended federal spending and prefer limited pilots.
Relative to its intended legislative type, this bill creates new substantive authorities for HHS to conduct research and award grants aimed at early detection and intervention for uterine fibroids and requires biennial reporting.
The bill authorizes the Secretary of Health and Human Services to conduct and support research and to develop evidence-based strategies to increase early detection of and intervention for uterine fibroids.
It allows the Secretary to award grants to States to implement programs (including screening and advanced gynecological imaging, patient navigation, public awareness campaigns, and measures to facilitate access) and gives priority to programs serving socially vulnerable populations at elevated risk.
The Secretary may also award grants for research on disparities in pain control and uterine fibroid surgical treatment and on intrauterine conditions such as Asherman’s Syndrome.
Based solely on the bill text, this is a modest, administratively straightforward public-health grant and research bill with low ideological salience and features that can attract bipartisan support. Major uncertainties include the absence of appropriation language (funding must be secured elsewhere), potential competing priorities in committee and on the floor, and the Senate’s procedural hurdles. If funded and paired with an appropriations vehicle or included in a larger health package, its chance to become law improves materially.
Relative to its intended legislative type, this bill creates new substantive authorities for HHS to conduct research and award grants aimed at early detection and intervention for uterine fibroids and requires biennial reporting. Its purpose is clear and basic program elements are present, but operational detail and fiscal scaffolding are limited.
Funding and scope: liberals expect robust funding and coverage actions; conservatives worry about open-ended federal spending and prefer limited pilots.
These are examples from the analysis, not a ranked list of the most-affected groups.
Funding and scope: liberals expect robust funding and coverage actions; conservatives worry about open-ended federal spending and prefer limited pilots.
A mainstream liberal would likely view this bill positively as a targeted, health-focused effort to address a condition that disproportionately affects women — particularly women of color — and to reduce disparities in access and outcomes.
They would welcome the emphasis on research, evidence-based strategies, and priority for socially vulnerable populations.
They would want stronger guarantees around funding, insurance coverage, and incorporation of reproductive-justice-aligned safeguards, and may press for inclusive definitions of services beyond screening (e.g., access to non-surgical alternatives and affordable care).
A mainstream centrist would generally view the bill as a reasonable, narrowly focused public health measure that addresses a specific medical condition and health disparity.
They would appreciate the emphasis on evidence-based strategies and reporting requirements but would seek clarity on costs, measurable outcomes, and whether the program overlaps with existing federal or state efforts.
A centrist would likely support the bill if accompanied by clear fiscal and programmatic details and guardrails to prevent duplication and ensure accountability.
A mainstream conservative would be cautiously skeptical of authorizing new federal grant programs and research mandates without clear funding and justification.
While supportive of improving women’s health in principle, they would be concerned about federal expansion, ongoing taxpayer costs, administrative burden, and possible intrusion into medical decision-making.
This persona might be open to targeted, time-limited, or state-driven approaches with limited federal spending and clear demonstration of benefit.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Based solely on the bill text, this is a modest, administratively straightforward public-health grant and research bill with low ideological salience and features that can attract bipartisan support. Major uncertainties include the absence of appropriation language (funding must be secured elsewhere), potential competing priorities in committee and on the floor, and the Senate’s procedural hurdles. If funded and paired with an appropriations vehicle or included in a larger health package, its chance to become law improves materially.
The bill has not accumulated any surfaced votes yet.
Funding and scope: liberals expect robust funding and coverage actions; conservatives worry about open-ended federal spending and prefer li…
Based solely on the bill text, this is a modest, administratively straightforward public-health grant and research bill with low ideologica…
Relative to its intended legislative type, this bill creates new substantive authorities for HHS to conduct research and award grants aimed at early detection and intervention for uterine fibroids and requires biennial…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.